Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• Gilead Sciences pays a quarterly dividend of $0.82 per share, or roughly $3.28 annualized, for a dividend yield of about 2.5%.
• The company has raised its dividend for more than 10 consecutive years, supported by a modest but consistent low-single-digit annual growth rate.
• The dividend appears well covered, with a payout ratio near 45% of earnings and around 40% of free cash flow (FCF).
• Gilead generates substantial operating cash flow, which comfortably funds its dividend alongside share buybacks and pipeline investment.
• The stock suits income-focused and conservative investors seeking a reliable, growing payout rather than an exceptionally high yield.

Dividend Overview

Gilead Sciences, Inc. (GILD), a global biopharmaceutical company best known for its HIV treatments, maintains a well-established quarterly dividend. The company currently pays $0.82 per share each quarter, which annualizes to approximately $3.28 per share and translates to a dividend yield of roughly 2.5%. Dividends are distributed on a quarterly schedule, typically declared in February, May, August, and November, with ex-dividend dates falling in March, June, September, and December.

Gilead is best characterized as a modest-yield dividend growth stock rather than a high-yield income play. Its yield is neither among the highest in the pharmaceutical sector nor negligible, and the company has demonstrated a clear commitment to returning cash to shareholders through steady annual increases. For investors, this profile offers a balance between current income and a track record of gradually rising payouts.

Dividend History and Growth

Gilead's dividend history reflects a deliberate, consistent strategy. The company initiated a dividend in 2015 and has increased it every year since, now spanning more than a decade of consecutive annual raises. The pace of those increases has been measured: the quarterly payment rose from $0.75 in 2023 to $0.77 in 2024, $0.79 in 2025, and $0.82 in 2026. This works out to an average annual dividend growth rate of roughly 3% over the past five years.

Rather than delivering large jumps, Gilead prioritizes reliability. The company has never cut its dividend, and its increases, while modest, have been predictable and steady. This approach signals a long-term capital-allocation philosophy focused on sustaining the payout through varying market and pipeline conditions, making the dividend a dependable component of shareholder returns.

Dividend Sustainability and Payout Ratio

Gilead's dividend looks well supported by its financials. The payout ratio, which measures dividends as a percentage of earnings, sits near 45% based on trailing results, while dividends consume only about 31% to 40% of free cash flow (FCF). Both figures leave meaningful headroom, indicating the company is not stretching its earnings or cash generation to fund shareholder payouts.

That cash generation is substantial. In fiscal 2025, Gilead produced roughly $10 billion in operating cash flow while paying about $4 billion in dividends, meaning the payout was covered multiple times over. The company also maintains a strong balance sheet and continues to invest in its drug pipeline and acquisitions without jeopardizing the dividend. While revenue remains concentrated in its HIV franchise, long patent protections on key products such as Biktarvy provide time for diversification, supporting the durability of the income stream.

Dividend Compared to Industry Peers

Within large-cap pharmaceuticals and biotech, Gilead's dividend yield of around 2.5% sits in the middle of the pack. It is lower than higher-yielding peers such as PFE and BMY, which typically offer yields well above Gilead's, but higher than many growth-oriented biotech companies that pay little or no dividend at all. Compared with diversified healthcare names like JNJ and MRK, Gilead's yield is broadly similar, though its dividend growth rate has been more conservative in recent years.

What distinguishes Gilead is the combination of a dependable payout, a low payout ratio, and strong cash flow rather than an outsized yield. Investors seeking maximum current income may find higher yields elsewhere in the sector, while those prioritizing reliability and gradual growth may view Gilead's profile favorably.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market efficiently. It enables users to scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, volatility, fundamentals, and AI-driven signals. The screener can help identify dividend stocks, income-focused investments, trending names, and breakout candidates, saving time compared with manual research. Investors exploring dividend opportunities like GILD can use the AI Screener to compare yields, growth, and financial metrics across the market.

Is This Stock Attractive for Dividend Investors?

Gilead Sciences may appeal most to conservative, income-oriented, and long-term dividend investors who prioritize reliability over a high current yield. The stock's combination of a moderate payout ratio, robust free cash flow, and more than a decade of uninterrupted dividend growth makes it a candidate for investors seeking a stable and gradually rising income stream. Its relatively low volatility and defensive healthcare exposure can also suit investors looking for a steadier holding within a diversified portfolio.

However, the stock may be less compelling for investors who require a high starting yield or rapid dividend growth. Gilead's yield is moderate by sector standards, and its annual increases have been modest. Investors should also weigh the concentration of revenue in its HIV franchise and the inherent risks of pharmaceutical pipelines and pricing pressures. Overall, Gilead presents a balanced profile: dependable income with modest growth, rather than aggressive yield or growth characteristics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations